October, 2010:

• Sandoz recalls certain lots of Methotrexate Injection
• Latuda approved for schizophrenia
• Sprycel gains indication for Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML)
• B. Braun recalls seven lots of heparin
• Orazyme Dry Mouth Mouthwash for xerostomia
• Phase 2 study of CPX-351 for the treatment of acute myeloid leukemia (AML)
• Phase 2 study of ataluren for the treatment of nonsense mutation methylmalonic acidemia (nmMMA)
• Phase 2 study of rHuPH20 for type 1 and type 2 diabetes
• Phase 3 trial of lixisenatide for treatment of type 2 diabetes
• Phase 3 study of linagliptin for treating type 2 diabetes
• Phase 3 trial of dapagliflozin plus metformin for type 2 diabetes
• Phase 2 study of Androxal for type 2 diabetes in hypogonadal men
• FDA issues complete response letter to NDA for lorcaserin
• Phase 3 trials of fidaxomicin for the treatment of Clostridium difficile infection (CDI)
• REMS approved for Nuvigil and Provigil
• Hyland's Teething Tablets recalled
• Lo Loestrin FE oral contraceptive approved
• Invirase labeling updated to include cardiac risk with Norvir
• Fentanyl transdermal 25mcg/hr patches recalled
• GnRH agonists labeling updated to include diabetes and cardiovascular risk
• Herceptin approved for HER2-positive metastatic stomach cancer
• Pradaxa approved for stroke risk reduction
• Phase 2 trial of CAL-101 for the treatment of chronic lymphocytic leukemia (CLL)
• Tylenol 8 Hour caplets recalled
• Preservative-free Garamycin ophthalmic ointment available
• Baraclude approved for chronic hepatitis B with decompensated liver disease
• Bromday approved for post-cataract extraction inflammation and ocular pain reduction
• Botox gains indication for chronic migraine
• H.P. Acthar Gel approved for infantile spasms
• FDA approves REMS for Gabitril
• FDA warns against over-the-counter chelation products
• Bisphosphonates labeling updated to include atypical fractures warning
• Vivitrol approved for opioid dependence
• Phase 2 trial of brentuximab vedotin for the treatment of anaplastic large cell lymphoma (ALCL)
• Phase 2 trial of GDC-0449 for the treatment of operable basal cell carcinoma (BCC)
• Systane Balance lubricant eye drops for Meibomian Gland Dysfunction
• Cefepime now available for use in DUPLEX Drug Delivery System
• FDA approves Atelvia for osteoporosis
• FDA warns against Slimming Beauty Bitter Orange Slimming Capsules
• MPR Everywhere Contest winner
• Meridia to be withdrawn from market
• MPR Everywhere Contest - Honorable Mention
• MPR Everywhere Contest - Funniest Entries
• Phase 2 study of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC)
• Phase 3 study of Vectibix for the treatment of metastatic colorectal cancer (mCRC)
• Phase 2 study of tasocitinib for the treatment of plaque psoriasis
• Phase 3 study update of D-tagatose for type 2 diabetes
• Aridol Bronchial Challenge Test Kit approved
• Tamiflu available for 2010-2011 influenza season
• Phase 2a study of plecanatide for the treatment of chronic constipation (cc)
• VeriPsych schizophrenia diagnostic aid available
• Xeomin available for cervical dystonia and blepharospasm
• Suprep Bowel Prep Kit available
• Kapvay approved for ADHD
• FDA halts marketing of unapproved colchicine